Mesa Laboratories Inc. 10-Q Summary
Business Context and Reporting Period
Mesa Laboratories, Inc. is a smaller reporting company that manufactures and distributes electronic measurement systems and disposables for niche applications, including renal treatment, food processing, medical sterilization, and pharmaceutical processing. This report covers the quarterly period ended June 30, 2009.
Key Financial Metrics
| Metric | Q1 2010 (Ended June 30, 2009) | Q1 2009 (Ended June 30, 2008) |
|---|---|---|
| Net Sales | $4,977,000 | $5,054,000 |
| Gross Profit | $2,983,000 | $3,204,000 |
| Gross Margin | 60% | 63% |
| Net Income | $1,026,000 | $1,016,000 |
| Diluted EPS | $0.31 | $0.31 |
| Operating Cash Flow | $2,032,000 | $1,153,000 |
| Cash and Equivalents | $10,759,000 | $6,390,000 |
| Current Ratio | 13:1 | 11:1 |
| Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 2% ($77,000) year-over-year. This was driven by a 26% decline in Datatrace product sales due to delayed capital spending by industrial customers, partially offset by a 16% increase in Raven product sales and a 12% increase in medical revenues.
- Margins: Gross margin declined from 63% to 60%. Management attributed this to a shift in product mix toward Raven products, which have lower margins compared to Medical and Datatrace products.
- Expenses: Selling, General & Administrative (SG&A) expenses decreased significantly from $1,495,000 to $1,223,000, and R&D expenses dropped from $173,000 to $152,000.
- Liquidity: Cash and cash equivalents increased by $1,648,000 to $10.76 million, driven by strong operating cash flow of $2.03 million.
Outlook, Risks, and Management Commentary
- Outlook: Management is cautiously optimistic about improving Datatrace sales trends in the latter part of fiscal 2010. They continue to monitor cost reduction programs and price increases to improve gross margins.
- Capital Allocation: The company maintains a share repurchase program (up to 300,000 shares) and paid a quarterly dividend of $0.10 per share. No debt is currently outstanding.
- Risks: Key risks include general economic conditions affecting capital spending, competition in data logging and dialysis markets, and the impact of lower interest rates on investment income.
- Unusual Items: Lower interest income on surplus cash due to softening rates and a higher anticipated income tax rate for fiscal 2010 impacted net income.
Investor Verification Checklist
- Verify the sustainability of the 16% growth in Raven product sales versus the 26% decline in Datatrace sales.
- Monitor the effectiveness of cost reduction and pricing strategies to reverse the gross margin decline from 63% to 60%.
- Confirm the timeline for the completion of the $140,000 bottling equipment purchase to automate dialysis solution production.
- Review the impact of the higher anticipated income tax rate for fiscal 2010 on future net income.
- Assess the progress of the new Micropack RF product development and its potential to offset declines in legacy Datatrace lines.